Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Targeting Hypoxia and Hypoxia-Inducible Factor-1 in the Tumor Microenvironment for Optimal Cancer Immunotherapy Publisher Pubmed



Kheshtchin N1, 2 ; Hadjati J3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  2. 2. Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  3. 3. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Cellular Physiology Published:2022


Abstract

The development of new strategies of anticancer immunotherapies has provided promising approaches in the treatment of solid tumors. However, despite the improved survival in responders, most of the patients show incomplete responses with a lack of remarkable clinical improvement. Hypoxia has been identified as a common characteristic of solid tumors contributing to different aspects of tumor progression, including invasion, metastasis, and the creation of the immunosuppressive tumor microenvironment. Hypoxia, through its main mediator, hypoxia-inducible factor-1 (HIF-1) is also associated with the limited efficacy of immunotherapies. Therefore, designing new strategies for immunotherapy implicating therapeutic targeting of HIF-1 molecules may enhance the clinical effectiveness of immunotherapy. Here, we discuss the contribution of hypoxia to the development of the immunosuppressive tumor microenvironment. We will also outline different strategies for targeting hypoxia to provide insight into the therapeutic potential of the application of such strategies to improve the clinical benefit of cancer immunotherapy. © 2021 Wiley Periodicals LLC.
Related Docs
View other Related Docs
1. Pro-Tumorigenic Functions of Macrophages at the Primary, Invasive and Metastatic Tumor Site, Cancer Immunology# Immunotherapy (2020)
2. Hypoxia Inducible Factors in the Tumor Microenvironment As Therapeutic Targets of Cancer Stem Cells, Life Sciences (2019)
3. Tumor Immunology, Clinical Immunology (2022)
4. The Role of Myeloid-Derived Suppressor Cells in Lung Cancer and Targeted Immunotherapies, Expert Review of Anticancer Therapy (2022)
5. Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy, Immune Network (2019)
6. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
7. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
8. Exhaustion of T Lymphocytes in the Tumor Microenvironment: Significance and Effective Mechanisms, Cellular Immunology (2017)
Experts (# of related papers)
View all Related Experts
Fatemeh Atyabi (16)
Nima Rezaei (15)
Other Related Docs
9. The Role of Inflammatory Cytokines and Tumor Associated Macrophages (Tams) in Microenvironment of Pancreatic Cancer, Cytokine and Growth Factor Reviews (2018)
10. Inhibition of Hif-1Α Enhances Anti-Tumor Effects of Dendritic Cell-Based Vaccination in a Mouse Model of Breast Cancer, Cancer Immunology# Immunotherapy (2016)
11. Genetic and Pharmacological Targeting of A2a Receptor Improves Function of Anti-Mesothelin Car T Cells, Journal of Experimental and Clinical Cancer Research (2020)
12. Downregulation of A2ar by Sirna Loaded Peg-Chitosan-Lactate Nanoparticles Restores the T Cell Mediated Anti-Tumor Responses Through Blockage of Pka/Creb Signaling Pathway, International Journal of Biological Macromolecules (2019)
13. Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy, Nanomedicine: Nanotechnology# Biology# and Medicine (2020)
14. Catalase Application in Cancer Therapy: Simultaneous Focusing on Hypoxia Attenuation and Macrophage Reprogramming, Biomedicine and Pharmacotherapy (2022)
15. Px-478, an Hif-1Α Inhibitor, Impairs Mesocar T Cell Antitumor Function in Cervical Cancer, Frontiers in Oncology (2024)
16. Concomitant Blockade of A2ar and Ctla-4 by Sirna-Loaded Polyethylene Glycol-Chitosan-Alginate Nanoparticles Synergistically Enhances Antitumor T-Cell Responses, Journal of Cellular Physiology (2020)
17. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
18. Tumor-Associated Macrophages and Epithelial–Mesenchymal Transition in Cancer: Nanotechnology Comes Into View, Journal of Cellular Physiology (2018)
19. Myeloid-Derived Suppressor Cells (Mdscs) Depletion by Cabozantinib Improves the Efficacy of Anti-Her2 Antibody-Based Immunotherapy in a 4T1-Her2 Murine Breast Cancer Model, International Immunopharmacology (2022)
20. Recruited Bone Marrow Derived Cells, Local Stromal Cells and Il-17 at the Front Line of Resistance Development to Anti-Vegf Targeted Therapies, Life Sciences (2019)
21. Increased Efficacy of a Dendritic Cell–Based Therapeutic Cancer Vaccine With Adenosine Receptor Antagonist and Cd73 Inhibitor, Tumor Biology (2017)
22. The Roles of Metabolic Profiles and Intracellular Signaling Pathways of Tumor Microenvironment Cells in Angiogenesis of Solid Tumors, Cell Communication and Signaling (2022)
23. Cd73 Specific Sirna Loaded Chitosan Lactate Nanoparticles Potentiate the Antitumor Effect of a Dendritic Cell Vaccine in 4T1 Breast Cancer Bearing Mice, Journal of Controlled Release (2017)
24. The Immunobiology of Myeloid-Derived Suppressor Cells in Cancer, Tumor Biology (2016)
25. Glioblastoma Cancer Stem Cell Biology: Potential Theranostic Targets, Drug Resistance Updates (2019)
26. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
27. Roles of Myeloid-Derived Suppressor Cells in Cancer Metastasis: Immunosuppression and Beyond, Archivum Immunologiae et Therapiae Experimentalis (2019)
28. Combined Inhibition of Cd73 and Zeb1 by Arg-Gly-Asp (Rgd)-Targeted Nanoparticles Inhibits Tumor Growth, Colloids and Surfaces B: Biointerfaces (2021)
29. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
30. Association of Grp78, Hif-1Α and Bag3 Expression With the Severity of Chronic Lymphocytic Leukemia, Anti-Cancer Agents in Medicinal Chemistry (2020)
31. The Role of T Helper 17 and Regulatory T Cells in Tumor Microenvironment, Immunopharmacology and Immunotoxicology (2019)
32. Blockage of Immune Checkpoint Molecules Increases T-Cell Priming Potential of Dendritic Cell Vaccine, Immunology (2020)
33. Silencing of Hif-1Α/Cd73 Axis by Sirna-Loaded Tat-Chitosan-Spion Nanoparticles Robustly Blocks Cancer Cell Progression, European Journal of Pharmacology (2020)
34. Th17/Treg Immunoregulation and Implications in Treatment of Sulfur Mustard Gas-Induced Lung Diseases, Expert Review of Clinical Immunology (2017)
35. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
36. Regulatory T Cells in Breast Cancer As a Potent Anti-Cancer Therapeutic Target, International Immunopharmacology (2020)
37. A Narrative Review of Tumor-Associated Macrophages in Lung Cancer: Regulation of Macrophage Polarization and Therapeutic Implications, Translational Lung Cancer Research (2021)
38. Anti-Angiogenic Effects of Cd73-Specific Sirna-Loaded Nanoparticles in Breast Cancer-Bearing Mice, Journal of Cellular Physiology (2018)
39. Adenosine and Adenosine Receptors in the Immunopathogenesis and Treatment of Cancer, Journal of Cellular Physiology (2018)
40. Coinhibition of S1pr1 and Gp130 by Sirna-Loaded Alginate-Conjugated Trimethyl Chitosan Nanoparticles Robustly Blocks Development of Cancer Cells, Journal of Cellular Physiology (2020)
41. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
42. Understanding the Tumor Microenvironment for Effective Immunotherapy, Medicinal Research Reviews (2021)
43. A Review on the Role of M2 Macrophages in Bladder Cancer; Pathophysiology and Targeting, International Immunopharmacology (2019)
44. Targeted Anti-Mitochondrial Therapy: The Future of Oncology, Genes (2022)
45. Tumor-Associated Macrophages: Role in Cancer Development and Therapeutic Implications, Cellular Oncology (2019)
46. Macrophage’S Role in Solid Tumors: Two Edges of a Sword, Cancer Cell International (2023)
47. Codelivery of Stat3 Sirna and Bv6 by Carboxymethyl Dextran Trimethyl Chitosan Nanoparticles Suppresses Cancer Cell Progression, International Journal of Pharmaceutics (2020)
48. Cancer-Associated Fibroblasts (Cafs) and Tumor-Associated Macrophages (Tams); Where Do They Stand in Tumorigenesis and How They Can Change the Face of Cancer Therapy?, European Journal of Pharmacology (2022)
49. Blockade of Ctla-4 Increases Anti-Tumor Response Inducing Potential of Dendritic Cell Vaccine, Journal of Controlled Release (2020)
50. Nanomedicine for Improvement of Dendritic Cell-Based Cancer Immunotherapy, International Immunopharmacology (2020)